1. ALLA AKTIER
  2. NYHETER
  3. SANIONA

Saniona

Nyheter Saniona Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Meet Saniona at several conferences during the spring

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, will be presenting at several investor and partnering conferences during the spring and summer.

Below an overview of places where you can currently meet Saniona and hear more about our programs and strategy.
Please also visit our website www.saniona.com for an updated list of investor and partnering conferences Saniona will attend.

Saniona conference participation:

Stockholm Corporate finance Day, Stockholm (March 17)

Nordic-American Healthcare Conference, New York (March 25-26)

Redeye Healthcare Day, Stockholm (April 14)

HC Andersen Capital Conference, Copenhagen (April 16)

Aktiespararna Aktiedagarna, Stockholm (June 9)

BIO International Convention, San Diego (June 22-25)

For more information, please contact
Johnny Stilou, CFO, +45 21227227; johnny.stilou@saniona.com

About Saniona
Saniona is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders. The company’s internal pipeline includes SAN2668 for paediatric epilepsy syndromes, SAN2219 for epilepsy, and SAN2465 for major depressive disorder. Saniona has established strategic collaborations with leading pharmaceutical companies, including Jazz Pharmaceuticals, which holds global rights to SAN2355 for epilepsy, Acadia Pharmaceuticals, which holds worldwide rights to ACP-711 for essential tremor, and with Medix, which holds rights to tesofensine for obesity in Mexico, where a market authorization application is currently under review, and Argentina. Saniona’s ion channel discovery platform is further validated through research collaborations with Boehringer Ingelheim, AstronauTx, and Cephagenix. Headquartered in Copenhagen, Saniona is listed on the Nasdaq Stockholm Main Market.
For more information, visit www.saniona.com.

Attachments
Meet Saniona at several conferences during the spring

Datum 2026-03-12, kl 08:00
Källa MFN
Bifogade filer
Meet Saniona at several conferences during the spring